AI Proteins

We're recruiting a Research Associate to join our Bioprocess Development team. This is a wet lab role ideally suited for someone graduating college this spring who is excited to join a team pioneering a new therapeutic modality

Check it out! 👇
www.aiproteins.com/open-positio...

AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think ...

I had a great time nerding out about protein design with @nickpolizzi.bsky.social, and an enormous thanks to @biotechtv.bsky.social and @massbio.bsky.social for hosting us!

www.biotechtv.com/post/chris-b...

Chris Bahl on the Conundrum of Biotech Platforms YouTube video by Provolut

Thanks for the fun conversation Ingmar Schuster, and for the opportunity to share more about what we're building at @aiproteins.com!

youtu.be/7O0s5AY46U0

AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.

See the official press release for details:
www.businesswire.com/news/home/20...

Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.

The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.

endpoints.news/boston-biote...

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

The secret language of cells — and how to "speak" it What if medicines could "speak" directly to your cells? Protein designer and TED Fellow Chris Bahl introduces a new generation of miniproteins: AI-designed medicines that can deliver detailed instruct...

My new @ted.com talk from the main stage just went live!

go.ted.com/chrisbahl

🧵👇

We're #hiring a Scientist in Mass Spectrometry!

Apply today or share this post with your network: www.linkedin.com/jobs/view/42...
(ignore what linkedin says - the search is still open)

Interested? Please email your CV to: careers@aiproteins.bio

His expertise and leadership are essential as we continue to industrialize our design-build-test process for drug discovery and work to bring #miniprotein medicines to patients across many diseases.

James has been a pivotal force in building our protein engineering approach, and as #CTO, he'll be driving the expansion of our core technology platform, integrating machine learning, synthetic biology, robotics, and large-scale data analysis to create entirely novel protein therapeutics

Congratulations to Dr. James Bowman on his promotion to Chief Technology Officer!

www.businesswire.com/news/home/20...

I am overjoyed to announce that James Bowman has been promoted to Chief Technology Officer at @aiproteins.com!

🧵👇

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

It was an honor to speak from the main stage at TED last week about our work at AI Proteins

Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

AI Proteins Appoints Philip E. Brandish, PhD as Chief Development Officer AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel miniprotein therapeutics, today announced the appointment of

Welcome Phil Brandish, Chief Development Officer, to the AI Proteins team!

www.businesswire.com/news/home/20...

We're delighted to share that our #Founder Chris Bahl @cdbahl.bsky.social is now our CEO!

So, I might have ended up on the jumbotron at the Celtics game proudly wearing my @aiproteins.bsky.social colors

Mireia Solà Colom, Head of Immunotherapeutics at AI Proteins, presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

BMS inks deal with AI Proteins; Terns’ early-stage leukemia data Bristol Myers Squibb partners with AI Proteins for miniprotein development, with up to $400M in milestones. Terns Pharmaceuticals reports positive Phase 1 data for TERN-701. Six biotechs seek Hong Kon...

and more coverage from Endpoints News @endpts.com

endpts.com/bms-inks-dea...

Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M Bristol Myers Squibb has

Exciting times at @aiproteins.bsky.social ! We are getting so close to see our drugs helping patients!
www.fiercebiotech.com/biotech/bris...

Bristol Myers Squibb taps AI Proteins in drug discovery collaboration worth up to $400M Bristol Myers Squibb has

You can read more about our exciting new collaboration with Bristol Myers Squibb in this coverage from Fierce Biotech
www.fiercebiotech.com/biotech/bris...

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

AI Proteins is excited to partner with @bms-news.bsky.social to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes
www.businesswire.com/news/home/20...

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

We've got some very exciting news to share!

businesswire.com/news/home/20...

and here's a 🧵 about the journey from academia to
@aiproteins.bsky.social

We're excited that Mireia Solà Colom, our Head of Immunotherapeutics will share some of our latest work on immune cell engagers at @bpdmc.bsky.social next month!

Our founder, President and CSO Chris Bahl @cdbahl.bsky.social went to the Falling Walls Science Summit last week to explain how we make #miniprotein therapeutics with unprecedented ability to control cellular behavior - you can check out the recording 👇
www.youtube.com/live/zB6-iUB...